+

WO2004071392A3 - Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) - Google Patents

Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) Download PDF

Info

Publication number
WO2004071392A3
WO2004071392A3 PCT/EP2004/000784 EP2004000784W WO2004071392A3 WO 2004071392 A3 WO2004071392 A3 WO 2004071392A3 EP 2004000784 W EP2004000784 W EP 2004000784W WO 2004071392 A3 WO2004071392 A3 WO 2004071392A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
disorders
muscarinic
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/000784
Other languages
French (fr)
Other versions
WO2004071392A2 (en
WO2004071392A8 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2004071392A2 publication Critical patent/WO2004071392A2/en
Publication of WO2004071392A8 publication Critical patent/WO2004071392A8/en
Publication of WO2004071392A3 publication Critical patent/WO2004071392A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention provides a human M4 which is associated with the disorders of the gastroenterology system, disorders of the peripheral and central nervous system, hematology diseases, cardiovascular diseases, repiratory diseases and inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the gastroenterology system, disorders of the peripheral and central nervous system, hematology diseases, cardiovascular diseases, repiratory diseases and inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of M4 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/000784 2003-02-11 2004-01-29 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) WO2004071392A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002647 2003-02-11
EP03002647.0 2003-02-11

Publications (3)

Publication Number Publication Date
WO2004071392A2 WO2004071392A2 (en) 2004-08-26
WO2004071392A8 WO2004071392A8 (en) 2004-10-14
WO2004071392A3 true WO2004071392A3 (en) 2005-01-06

Family

ID=32864920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000784 WO2004071392A2 (en) 2003-02-11 2004-01-29 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4)

Country Status (1)

Country Link
WO (1) WO2004071392A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118987229A (en) * 2024-09-10 2024-11-22 北京大学 Application of Chrm-4 specific antagonist in preparation of medicines for treating lung type 2 immune inflammatory diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036609A2 (en) * 2000-10-31 2002-05-10 Genaissance Pharmaceuticals, Inc. Haplotypes of the chrm4 gene
EP1221443A1 (en) * 1999-10-13 2002-07-10 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221443A1 (en) * 1999-10-13 2002-07-10 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
WO2002036609A2 (en) * 2000-10-31 2002-05-10 Genaissance Pharmaceuticals, Inc. Haplotypes of the chrm4 gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MIGUEL JOAO C ET AL: "Muscarinic receptor subtypes mediate stimulatory and paradoxical inhibitory effects on an insulin-secreting beta cell line", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1569, no. 1-3, 15 January 2002 (2002-01-15), pages 45 - 50, XP002289358, ISSN: 0006-3002 *
OKTAY S ET AL: "Evidence for the presence of muscarinic M2 and M4 receptors in guinea-pig gallbladder smooth muscle", JOURNAL OF AUTONOMIC PHARMACOLOGY, vol. 18, no. 4, August 1998 (1998-08-01), pages 195 - 204, XP002289357, ISSN: 0144-1795 *
ZLOTOS D P ET AL: "MUSCARINIC RECEPTOR AGONISTS AND ANTAGONISTS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 9, no. 8, 1999, pages 1029 - 1053, XP001007672, ISSN: 1354-3776 *

Also Published As

Publication number Publication date
WO2004071392A2 (en) 2004-08-26
WO2004071392A8 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004008153A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens putative neurotransmitter receptor (pnr)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2003065044A8 (en) Diagnostics and therapeutics for diseases associated with gpr72
WO2004071392A8 (en) Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2003083135A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2004082566A3 (en) Diagnostics and therapeutics for diseases associated with complement component 3a receptor 1 (c3ar1)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2003100436A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 10 (ccr10)
WO2003081257A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 1 (npff1)
WO2004015427A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2004 UNDER (30) REPLACE "Ä3002647.0" BY "03002647.0"

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载